Tech Company Financing Transactions
Apexian Pharmaceuticals Funding Round
Private investors participated in a $2.8 million funding round for Apexian Pharmaceuticals. The financing round was announced on 7/12/2018.
Transaction Overview
Company Name
Announced On
7/12/2018
Transaction Type
Venture Equity
Amount
$2,800,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 7 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
20 N. Meridian Guaranty Bldg. 801
Indianapolis, IN 46204
USA
Indianapolis, IN 46204
USA
Phone
Website
Email Address
Overview
Apexian Pharmaceuticals is an emerging clinical stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose groundbreaking work on APE1/Ref-1 redox protein signaling at the Indiana University School of Medicine has provided unique insight into this important biological target.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Broecker
Chief Medical Officer
Richard Messmann
Chief Operating Officer
Roger Miller
Chief Scientific Officer
Mark Kelley
VP - Operations
Jan Elkins
VP - R & D
James Wikel
VP - Regulatory Affairs
William Current
VP - Regulatory Affairs
Roberta Smithey
Browse more venture capital transactions:
Prev: 7/12/2018: DIRT Protocol venture capital transaction
Next: 7/12/2018: Double Helix Optics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs